Hovione Announces Enrollment of First Patient in MARS
A Phase 2 Clinical Trial for the Treatment of Moderate to Severe Inflammatory Rosacea with its Proprietary Minocycline Topical Gel
A Phase 2 Clinical Trial for the Treatment of Moderate to Severe Inflammatory Rosacea with its Proprietary Minocycline Topical Gel
Hovione announced today the appointment of Mr. Frédéric Kahn as Vice President Marketing and Sales, as of 1st September, 2017
HY02, a Proprietary Minocycline Sterile Ointment to Treat a Subset of Anterior Ocular Inflammation
Hovione announced today that it held on June 8th the official groundbreaking for the expansion of its New Jersey facility in East Windsor, USA
Loures, Portugal, June 6, 2016 – Hovione is pleased to announce the opening of its new sales and customer support office in Osaka, Japan.
Hovione today announced that it plans to host and operate a commercial-scale continuous manufacturing facility as part of an agreement with Vertex Pharmaceuticals
Hovione announced today that it is investing in specialized formulation capabilities.
Ms. Senft joined Hovione on the 1st October and will succeed Mr. Dave Hoffman Vice President Sales and Business Development when he retires in April 2016.
Hovione announced today the expansion of its New Jersey facility in East Windsor, USA.
Hovione announced today the installation of a new large scale spray drying unit in Loures, Portugal.